Track early Parkinson disease progression

Trial ID
NCT05767151
Official Title
The Chinese DENOVO Parkinson's Disease Registry
Goal
Track early Parkinson disease progression
Status
RECRUITING
Sponsor
Xiangya Hospital of Central South University
Study Type
OBSERVATIONAL
Enrollment
300 participants
Conditions
Parkinson Disease

Plain-Language Summary

The registry aims to map the early course of Parkinson's disease and find patterns or markers that could help with earlier diagnosis and better care down the road. It enrolls 300 people who are newly diagnosed and treatment naive, then collects standardized clinical assessments and follow-up data to see how symptoms and signs evolve over time. Eligible participants are 30 to 75 years old, diagnosed by MDS criteria with disease duration of two years or less, Hoehn-Yahr stage 2 or lower, not yet on antiparkinsonian drugs, and without cognitive impairment or other parkinsonism syndromes.

Locations

  • Xiangya Hospital of Central South University, Changsha, Hunan, China

Frequently Asked Questions

What is this trial testing?
This trial is studying an experimental treatment. The registry aims to map the early course of Parkinson's disease and find patterns or markers that could help with earlier diagnosis and better care down the road. It enrolls 300 people who are newly diagnosed and treatment naive, then collects standardized clinical assessments and follow-up data to see how symptoms and signs evolve over time. Eligible participants are 30 to 75 years old, diagnosed by MDS criteria with disease duration of two years or less, Hoehn-Yahr stage 2 or lower, not yet on antiparkinsonian drugs, and without cognitive impairment or other parkinsonism syndromes.
Who can participate?
Participants must be between 30 Years and 75 Years.
Where is this trial located?
This trial is recruiting at 1 location.
Does it cost anything to join?
No. There is no cost to participate. Study-related care and treatment are provided at no charge.
How long does the trial last?
This trial is estimated to last approximately 10 years.

View on ClinicalTrials.gov